by | May 19, 2024 | Publications
Clin Lymphoma Myeloma Leuk. 2024 Apr 26:S2152-2650(24)00153-8. doi: 10.1016/j.clml.2024.04.006. Online ahead of print. ABSTRACT PURPOSE: There is compelling evidence that CD4+ and CD8+T cells are dysfunctional in multiple myeloma, compromising their ability to control...
by | May 19, 2024 | Publications
Biofactors. 2024 May 17. doi: 10.1002/biof.2078. Online ahead of print. ABSTRACT Multiple myeloma (MM) is a blood cancer caused by uncontrolled growth of clonal plasmacells. Bone disease is responsible for the severe complications of MM and is caused by myeloma cells...
by | May 19, 2024 | Publications
Curr Oncol Rep. 2024 May 18. doi: 10.1007/s11912-024-01545-2. Online ahead of print. ABSTRACT PURPOSE OF REVIEW: As the treatment landscape for multiple myeloma (MM) continues to expand at a rapid pace, management of older adults and frail patients becomes...
by | May 18, 2024 | Publications
Clin Lymphoma Myeloma Leuk. 2024 Apr 19:S2152-2650(24)00154-X. doi: 10.1016/j.clml.2024.04.005. Online ahead of print. ABSTRACT INTRODUCTION: The therapeutic landscape in relapsed/refractory multiple myeloma (RRMM) has changed rapidly, with twenty-two drug approvals...
by | May 18, 2024 | Publications
Blood Cancer J. 2024 May 17;14(1):82. doi: 10.1038/s41408-024-01062-2. ABSTRACT Autologous stem cell transplantation (autoHCT) is considered standard of care for newly diagnosed multiple myeloma (MM). Although most patients eventually progress after autoHCT, a small...
by | May 18, 2024 | Publications
Biomed Pharmacother. 2024 May 16;175:116738. doi: 10.1016/j.biopha.2024.116738. Online ahead of print. ABSTRACT Despite significant advancements in multiple myeloma (MM) treatment in recent years, most patients will eventually develop resistance or experience relapse....
